Back to results
US 7,915,315 B2Granted
Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
AssigneeUniversity of Virginia Patent Foundation
InventorsKevin R. Lynch, Timothy L. Macdonald
Life of this patent
Estimating the term…
Abstract
Benzocycloheptyl analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors.
Claims13
A compound of Formula IA, IB, or IC:
- wherein W1, X1, Y1 and Z1 are independently O, CRa, CRaRb, N, NRc, or S;
- R1 and R2 are independently hydrogen, halo, halo(C1-C10)alkyl, cyano, —NRaRb, (C1-C20)alkyl, (C2-C20)alkynyl, (C1-C20)alkoxy, (C2-C26)alkoxyalkyl, (C3-C12)cycloalkyl, (C6-C10)aryl, (C7-C30)arylalkyl, (C2-C10)heterocyclic, (C4-C10)heteroaryl, or (C4-C10)heteroaryl(C1-C20)alkyl;
- wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl groups of R1 and R2 independently are optionally perfluorinated or optionally substituted with 1, 2, 3, or 4 groups where the substituent groups are independently hydroxy, halo, cyano, (C1-C10)alkoxy, C6-aryl, (C7-C24)arylalkyl, oxo (═O), or imino (═NRd), wherein one or more of the carbon atoms in the R1 or R2 alkyl groups can be independently replaced with non-peroxide oxygen, sulfur or NRc;
- the alkyl groups of R3 are optionally substituted with 1, or 2 hydroxyl groups;
- or
- R2 can be a group having formula II, III, IV, V, or VI;
- wherein each R7, R8, R9, R10, R11, R12, R13, and R14 is independently O, S, C, CR15, CR16R17, C═O, N or NR18;
- each R15, R16 and R17 is independently hydrogen, halo, (C1-C10)alkyl, (C6 -C10)aryl, (C1-C10)alkyl substituted with halo, hydroxy, (C1-C10)alkoxy, or cyano;
- and where R18 can be hydrogen or (C1-C10)alkyl;
- Z2 is hydrogen, halo, halo(C1-C10)alkyl, cyano, —NRaRb, (C1-C20)alkyl, (C2 -C20)alkenyl, (C2-C20)alkynyl, (C1-C20)alkoxy, (C2-C26)alkoxyalkyl, (C3-C12 )-cycloalkyl, (C6-C10)aryl, (C7-C30)arylalkyl, (C2-C10)heterocyclic, (C4 -C10)heteroaryl, or (C4-C10)heteroaryl(C1-C20)alkyl;
- the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl groups of Z2 are optionally perfluorinated or optionally substituted with 1, 2, 3, or 4 groups where the substituent groups are independently hydroxy, halo, cyano, (C1 -C10)alkoxy, C6-aryl, (C7-C24)arylalkyl, oxo (═O), or imino (═NRd), wherein one or more of the carbon atoms in the Z2 alkyl groups can be independently replaced with non-peroxide oxygen, sulfur or NRc;
- indicates one or more optional double bonds;
- Y2 is a bond (absent), O, S, C═O, or NRc, CH2;
- W2 is a bond;
- —CH2— and m is 1, 2, or 3, or W2 is (C═O)(CH2)1-5 and m is 1;
- wherein W2 is optionally interrupted with non-peroxide O, S, C═O, or NRc;
- n is 0, 1, 2, or 3;
- each represents an optional double bond;
- and q is 0, 1, 2, or 3;
- R3 is hydrogen, (C1-C10)alkyl, hydroxy(C1-C10)alkyl or (C1-C10)alkoxy;
- and
- R4 is hydroxyl (—OH), phosphate (—OPO3H2), phosphonate (—CH2PO3H2), alpha-substituted phosphonate;
- each Ra, Rb, Rc, and Rd is independently hydrogen, CF3 or (C1-C10)alkyl;
- or
- a pharmaceutically acceptable salt or ester thereof.
22 more elements
Dependencies are inferred from the claim text.